文献速递核素与放射性配体治疗肿瘤 PET/CT

白蛋白结合域融合C9亲和体靶向RPT治疗CEACAM5表达人源异种移植瘤的初步研究

Targeted RPT of CEACAM5-Expressing Human Xenografts Using an Albumin-Binding Domain-Fused C9 Affibody: Proof-of-Principle Study.
PubMed 文献 · J Nucl Med · 2026-09-10

本研究将靶向CEACAM5的亲和体二聚体C9与白蛋白结合域ABD035融合,经177Lu标记后评估其用于靶向放射性药物治疗的可行性。体外实验显示两种螯合剂构建体均具有可饱和的CEACAM5依赖性结合,24小时内化率约40%。体内实验表明DOTA构建体较DOTAGA构建体肾脏摄取显著更低,且较无ABD035的对照构建体肾脏摄取降低14倍(注射后4小时)、BxPC3肿瘤摄取提高3.6倍。单次注射12 MBq [177Lu]Lu-ABD035-C9-C9-DOTA显著延长荷瘤小鼠生存,毒性轻微且短暂。

要点

  • ABD035-C9-C9-DOTA较无ABD035对照构建体肾脏摄取降低14倍、肿瘤摄取提高3.6倍。
  • DOTA螯合构建体肾脏摄取显著低于DOTAGA螯合构建体。
  • 单次12 MBq [177Lu]Lu-ABD035-C9-C9-DOTA显著延长荷瘤小鼠生存,毒性轻微短暂。

核心结论

  • ABD035-C9-C9-DOTA是开发CEACAM5表达肿瘤靶向RPT的有前景候选分子。

研究设计与样本

  • 本研究为临床前实验研究,使用CEACAM5阳性BxPC3和LS174T细胞、CEACAM5阴性HT-29细胞进行体外结合、动力学和内化评估。
  • 体内生物分布比较在携带BxPC3异种移植瘤的BALB/c nu/nu小鼠中进行,比较[177Lu]Lu-ABD035-C9-C9-DOTA与[177Lu]Lu-ABD035-C9-C9-DOTAGA。
  • 对[177Lu]Lu-ABD035-C9-C9-DOTA进行生物分布测量以计算剂量学,并通过建模优化肿瘤控制概率。
  • 评估单次注射12 MBq [177Lu]Lu-ABD035-C9-C9-DOTA对BxPC3异种移植瘤生长的影响。

主要发现

  • [177Lu]Lu-ABD035-C9-C9-DOTA和[177Lu]Lu-ABD035-C9-C9-DOTAGA在体外均显示可饱和的CEACAM5依赖性结合,24小时内化率约40%,两者内化速率差异较小。
  • 体内[177Lu]Lu-ABD035-C9-C9-DOTA的肾脏摄取显著低于DOTAGA缀合变体。
  • 与无ABD035的[177Lu]Lu-C9-C9-DOTA参照构建体相比,[177Lu]Lu-ABD035-C9-C9-DOTA肾脏摄取显著降低14倍(注射后4小时),BxPC3异种移植瘤摄取提高3.6倍。
  • 该实验性RPT研究显示荷瘤小鼠生存显著延长,毒性轻微且短暂。

关键数值与推荐

  • ABD035-C9-C9分子量20,296 Da,对CEACAM5和albumin的亲和力分别为2.5 nM和1.9 nM。
  • 单次注射12 MBq [177Lu]Lu-ABD035-C9-C9-DOTA用于评估对BxPC3异种移植瘤生长的影响。
  • 与无ABD035参照构建体相比,肾脏摄取降低14倍(注射后4小时),BxPC3肿瘤摄取提高3.6倍。

临床怎么用

  • 临床前数据支持ABD035-C9-C9-DOTA作为CEACAM5靶向RPT的候选药物进一步开发。
  • DOTA螯合剂较DOTAGA有助于降低肾脏摄取,可能有利于降低肾毒性风险。

局限性

  • 本研究为临床前概念验证研究,结果尚未在人体中验证。
  • 毒性评估为轻微且短暂,但具体毒性指标和长期安全性数据未在摘要中详述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The carcinoembryonic antigen cell adhesion molecule 5 (CEACAM5) is highly overexpressed in carcinomas of different origins. Affibody molecules are non-immunoglobulin-based affinity proteins capable of in vivo recognition of cancer-associated targets. Affibody C9 was previously generated to bind selectively to CEACAM5. In an earlier in vivo study, C9 was engineered as a dimer, and the effects on the biodistribution from the addition of an N- or C-terminal-fused albumin-binding domain (ABD035) were investigated using 99mTc labeling. The variant ABD035-C9-C9 with N-terminal ABD035 placement (20,296 Da; affinities of 2.5 and 1.9 nM to CEACAM5 and albumin, respectively) was found to provide the most favorable biodistribution for the delivery of cytotoxic payloads. In this study, we tested the hypothesis that ABD035-C9-C9 labeled with a cytotoxic radionuclide would be suitable for targeted radiopharmaceutical therapy (RPT). Methods: ABD035-C9-C9, labeled with the β-emitting radionuclide 177Lu via DOTA or DOTAGA chelators, was evaluated. CEACAM5-positive (BxPC3, LS174T) and CEACAM5-negative (HT-29) cell lines were used to assess binding specificity, kinetics, and internalization in vitro. The biodistribution of [177Lu]Lu-ABD035-C9-C9-DOTA and [177Lu]Lu-ABD035-C9-C9-DOTAGA was compared in BALB/c nu/nu mice with BxPC3 xenografts. The biodistribution of [177Lu]Lu-ABD035-C9-C9-DOTA was measured for dosimetry calculation. Modeling was performed to maximize tumor control probability. The effect of a single injection of 12 MBq of [177Lu]Lu-ABD035-C9-C9-DOTA on the growth of BxPC3 xenografts was evaluated. Results: In vitro, both [177Lu]Lu-ABD035-C9-C9-DOTA and [177Lu]Lu-ABD035-C9-C9-DOTAGA constructs demonstrated saturable, CEACAM5-dependent binding, with a minor difference in internalization rate (∼40% internalization after 24 h). In vivo, [177Lu]Lu-ABD035-C9-C9-DOTA showed significantly lower kidney uptake than the DOTAGA-conjugated variant. [177Lu]Lu-ABD035-C9-C9-DOTA demonstrated a significantly reduced renal uptake (14-fold, 4 h postinjection) and an increased uptake in BxPC3 xenografts (3.6-fold) compared with a [177Lu]Lu-C9-C9-DOTA reference construct without ABD035 This experimental RPT study demonstrated a significant increase in the survival of tumor-bearing mice and mild, transient toxicity. Conclusion: ABD035-C9-C9-DOTA is a promising candidate for the development of targeted RPT of CEACAM5-expressing tumors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Li R, Papalanis E, Oroujeni M, et al. Targeted RPT of CEACAM5-Expressing Human Xenografts Using an Albumin-Binding Domain-Fused C9 Affibody: Proof-of-Principle Study. J Nucl Med. 2026. PMID: 42722440. doi:10.2967/jnumed.126.272854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。